Cizzle Brands Corporation Schedules Second Fiscal Quarter 2025 Financial Results Webcast for Thursday, March 27, 2025 at 4:30 PM ET

Cizzle Brands Corporation Schedules Second Fiscal Quarter 2025 Financial Results Webcast for Thursday, March 27, 2025 at 4:30 PM ET

Following the release of Cizzle Brands' second fiscal quarter 2025 financial results, the Company's management team will be hosting a webcast to provide further insight regarding the results in the context of the Company's ongoing business activities.

Cizzle Brands Corporation (Cboe Canada: CZZL) (OTCQB: CZZLF) (Frankfurt: 8YF) ( the "Company" or "Cizzle Brands") , today announced its plans to release financial results for the second quarter of its fiscal 2025 year ended January 31, 2025 (" FQ2 2025 ") after market close on Monday, March 17, 2025. These results will be available on Cizzle Brands' profile on SEDAR+ ( http://www.sedarplus.ca/ ).

Cizzle Brands will conduct a webcast to discuss these results on the Thursday of the following week. Information regarding the webcast is provided below:

  • Date and Time: Thursday, March 27, 2025 at 4:30 pm Eastern
  • Scheduled Duration: Approximately one hour
  • Registration Link: https://streamyard.com/watch/htXpXqNJzhUR

The webcast's registration link may not be visible through some news aggregation services. Please refer to the News section of the Cizzle Brands' website for a version of this press release with the link. Alternatively, the link may be obtained by contacting Cizzle Brands' Investor Relations team.

Cizzle Brands' Founder, Chairman, and Chief Executive Officer John Celenza commented, "As a public company with our common shares traded in three different markets, we take pride in being transparent and communicative with our growing investor base. To that end, we are pleased to be hosting this webcast following the publication of our FQ2 2025 financial results, where we will be able to provide key, plain-language insights with respect to what is behind the numbers, and how they fit into our current operations as we continue to commercialize our brands CWENCH Hydration™ and Spoken Nutrition. Our management team is excited to deliver this presentation, and we encourage all current and prospective investors in Cizzle Brands to register to attend."

About Cizzle Brands Corporation

Cizzle Brands Corporation is a sports nutrition company that is elevating the game in health and wellness. Through extensive collaboration and testing with leading athletes and trainers across several elite sports, Cizzle Brands has launched two leading product lines in the sports nutrition category: (i) CWENCH Hydration™, a better-for-you sports drink that is now carried in over 1,200 stores in Canada, the United States, and Europe; and (ii) Spoken Nutrition, a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification. All Cizzle Brands products are designed to help people achieve their best in both competitive sports and in living a healthy, vibrant, active lifestyle.

For more information about Cizzle Brands, please visit: https://www.cizzlebrands.com/

For more information about CWENCH Hydration™, please visit: https://www.cwenchhydration.com

For more information about the CWENCH All Canadian Games, please visit: https://www.cwenchallcanadian.com

Notice Regarding Images and Links: This press release may contain images and/or links to outside web pages, which could play an important role in providing the full context of the news update being conveyed through this press release. Some news aggregation services may remove these images and/or links at their discretion. Therefore, readers are encouraged to access SEDAR+ or the News section of the Cizzle Brands Corporation website to view this press release containing all images and/or links as originally published.

On behalf of the Board of Directors of the Company,

Cizzle Brands Corporation

"John Celenza"

John Celenza, Founder, Chairman, and Chief Executive Officer

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This news release contains "forward-looking information" which may include, but is not limited to, information with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, such as, but not limited to: new products of the Company and potential sales and distribution opportunities. Such forward-looking information is often, but not always, identified by the use of words and phrases such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company.

Forward looking information involves known and unknown risks, uncertainties and other risk factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks include risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks, regulatory risks, financing, capitalization and liquidity risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company undertakes no obligation, except as otherwise required by law, to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors change.

Footnotes

1 72% sequential growth of CWENCH Hydration™ 10-count units sold from Cizzle Brands' Fiscal Q1 2025 to Fiscal Q2 2025 reflects unit sales increasing from 11,943 units to 20,543 units each quarter with this account

2 64% sequential growth of CWENCH Hydration™ 315-gram units sold from Cizzle Brands' Fiscal Q1 2025 to Fiscal Q2 2025 reflects unit sales increasing from 2,730 units to 4,478 units each quarter with this account

3 39% sequential growth of CWENCH Hydration™ RTD beverage units sold during the calendar month of September 2024 compared to the calendar month of January 2025 with this account reflects unit sales increasing from 11,695 units per month to 16,280 units per month

For further information, please contact:

Setti Coscarella
Head of Corporate Development
investors@cizzlebrands.com
1-844-588-2088

News Provided by Business Wire via QuoteMedia

CZZL:AQL
The Conversation (0)
Cizzle Brands Corporation (CBOE:CZZL)

Cizzle Brands Corporation

A Sports Nutrition Company Leading the Next Wave in Health and Wellness

A Sports Nutrition Company Leading the Next Wave in Health and Wellness Keep Reading...
Cizzle Brands Expands Availability of CWENCH Hydration at all Fortinos Locations in Ontario

Cizzle Brands Expands Availability of CWENCH Hydration at all Fortinos Locations in Ontario

Approximately two months after the chain-wide launch of CWENCH's hydration mix powder in Fortinos stores (February of 2025), CWENCH Hydration™ is now fully represented at Fortinos with the addition of its ready-to-drink Tetra Pak® format at all Fortinos locations, strengthening the footprint of... Keep Reading...
Cizzle Brands Strengthens U.S. Footprint of CWENCH Hydration With Availability at United Supermarkets in Texas

Cizzle Brands Strengthens U.S. Footprint of CWENCH Hydration With Availability at United Supermarkets in Texas

The placement of CWENCH Hydration™ at United Supermarkets, a well-known chain of supermarkets in central and northern Texas, is part of Cizzle Brands' plan to strategically add to its U.S. presence in 2025. Cizzle Brands Corporation (Cboe Canada: CZZL) (OTCQB: CZZLF) (Frankfurt: 8YF) ( the... Keep Reading...
Cizzle Brands Announces that All 134 Metro Locations in Ontario Will be Offering CWENCH Hydration Ready-to-Drink Beverages

Cizzle Brands Announces that All 134 Metro Locations in Ontario Will be Offering CWENCH Hydration Ready-to-Drink Beverages

The availability of CWENCH Hydration™ in its ready-to-drink format at all 134 Metro locations in Ontario follows only three months after the initial launch of CWENCH's Hydration Mix with Metro in its Ontario stores. Cizzle Brands Corporation (Cboe Canada: CZZL) (OTCQB: CZZLF) (Frankfurt: 8YF) (... Keep Reading...
Cizzle Brands' CWENCH Hydration Becomes USA Hockey's Official Hydration Partner

Cizzle Brands' CWENCH Hydration Becomes USA Hockey's Official Hydration Partner

As a proud supporter of grassroots hockey across North America, Cizzle Brands is embracing this opportunity to further enhance its U.S. presence with brand visibility throughout the entire USA Hockey network by virtue of this multi-year sponsorship. Cizzle Brands Corporation (Cboe Canada: CZZL)... Keep Reading...
Cizzle Brands Adds to its Presence in Ontario with Placements of CWENCH Hydration in Healthy Planet and Farm Boy

Cizzle Brands Adds to its Presence in Ontario with Placements of CWENCH Hydration in Healthy Planet and Farm Boy

The availability of CWENCH Hydration™ in Healthy Planet and Farm Boy, both of which are leading retailers in Ontario, will further enhance visibility and availability of the product as its market share continues to increase. Cizzle Brands Corporation (Cboe Canada: CZZL) (OTCQB: CZZLF)... Keep Reading...
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume... Keep Reading...
Appendix 4C and Quarterly Activities Report - September 2025

Appendix 4C and Quarterly Activities Report - September 2025

Invion Limited (IVX:AU) has announced Appendix 4C and Quarterly Activities Report - September 2025Download the PDF here. Keep Reading...
Nextech3D.ai Reports Strong 20% Q2 Sequential Revenue Growth With Gross Margins of 88% For the Three Months Ended September 30, 2025 ("Q2 2026")

Nextech3D.ai Reports Strong 20% Q2 Sequential Revenue Growth With Gross Margins of 88% For the Three Months Ended September 30, 2025 ("Q2 2026")

Key Year-over-Year Highlights:Gross Margin Expansion: Increased to 88%, up from 71%, representing a 17-point improvement.Operating Loss Reduced by 65%: Narrowed to $439,000, from $1.25 million in 2024.Net Loss Reduced by 63%: Improved to $482,000, compared to $1.31 million last year.Deferred... Keep Reading...
Doctor using tablet with medical icons overlayed.

Biotech and Pharma Market Update: Q3 2025 in Review

The third quarter was a pivotal period for both the biotech and pharmaceutical sectors, with regulatory developments and an increase in business deals shaping the landscape for the industries. Public biotech indexes rallied above critical levels last seen in 2021, with the NASDAQ Biotech Index... Keep Reading...
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 4 Canadian Biotech Stocks of 2025

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.Here the Investing News Network profiles the five best-performing Canadian biotech stocks on... Keep Reading...
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read... Keep Reading...

Latest Press Releases

Related News